Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00185094 · ClinicalTrials.gov registry record · Phase 4
A Comparison of the Effect of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on the Ability of Overweight Patients With High Blood Pressure to Respond to Insulin
A Phase 4 study of Hypertension and Insulin Resistance, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
- 10
- Study locations
NCT00185094: Completed Phase 4 study of Hypertension and Insulin Resistance, sponsored by Daiichi Sankyo.
NCT00185094 is a Phase 4 study of Hypertension and Insulin Resistance that has completed, run by Daiichi Sankyo. The registered enrollment target is 60 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (98% lower). The trial reports 10 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00185094, a Phase 4 study of Hypertension and Insulin Resistance, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
- 10
- Study locations
Study Summary
To examine the effect of three different blood pressure medications on the insulin sensitivity in overweight patients with high blood pressure.
Conditions Studied
Interventions
- DRUG Atenolol
- DRUG Olmesartan medoxomil
- DRUG Losartan potassium
Study Locations (10)
Texas
- - Dallas
- - San Antonio
Alabama
- - Birmingham
California
- - San Diego
Florida
- - Miami
Indiana
- - Indianapolis
Maryland
- - Baltimore
Massachusetts
- - Boston
Minnesota
- - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2004-02 |
| Est. Completion | 2005-07 |
| Phase | Phase 4 |
What the finished NCT00185094 record still lists
NCT00185094 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (98% lower).
The record links to 3 conditions, with Hypertension appearing as the primary indexed condition, and to 3 interventions - of which Atenolol is the first listed.
NCT00185094 lists 10 locations in 9 states (Texas, Alabama, California).
Frequently Asked Questions
What is clinical trial NCT00185094 about?
NCT00185094 is a clinical study titled "A Comparison of the Effect of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on the Ability of Overweight Patients With High Blood Pressure to Respond to Insulin". To examine the effect of three different blood pressure medications on the insulin sensitivity in overweight patients with high blood pressure.
What is the current status of trial NCT00185094?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2004-02. Estimated completion is 2005-07.
What conditions does trial NCT00185094 study?
This clinical trial studies the following conditions: Hypertension, Insulin Resistance, Metabolic Syndrome.
What interventions are being tested in trial NCT00185094?
The interventions under investigation include: Atenolol (DRUG), Olmesartan medoxomil (DRUG), Losartan potassium (DRUG).
Who is sponsoring clinical trial NCT00185094?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00185094 being conducted?
This trial has 10 study locations across Alabama, California, Florida, Indiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00185094's enrollment target sits among peer trials
60 345th of 470 higher than 116 of 470 other Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Treatment With Aspirin After Preeclampsia: TAP Trial
RECRUITING · Phase 4
-
Impact GLP-1 Agonists Following Bariatric
RECRUITING · Phase 4
-
Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study
RECRUITING · Phase 4
-
Bridging the Evidence-to-practice Gap
RECRUITING · Phase 4
-
Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension
RECRUITING · Phase 4
-
Secondhand Tobacco Smoke and Cardiovascular Disease
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia